Live Breaking News & Updates on Ublic Interest Litigation In India

Stay updated with breaking news from Ublic interest litigation in india. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Modification of coronavirus treatment protocol: Delhi HC rejects PIL

The Delhi High Court on Tuesday dismissed a Public Interest Litigation (PIL) seeking direction to the Central India, Indian Council of Medical Research (ICMR) and NITI Aayog regarding reconsideration of the prevalent treatment protocol for a mild case of COVID-19 and modify the treatment protocol in COVID-19.
The Bench of Justice DN Patel and Justice Jyoti Singh dismissed the petition and also imposed a fine of Rs 25,000 on the petitioner.
The court showed displeasure with the petition and said the respondents have enough experts to take a decision regarding protocols.
Additional Solicitor General (ASG) Chetan Sharma, appearing for the Central government, also opposed the petition and said various petitions are coming to the respondents and giving suggestions. ....

Vivek Sheel Aggarwal , Praveenk Sharma , Chetan Sharma , Justice Jyoti Singh , Amitesh Bakshi , Niramaya Research , Indian Council Of Medical Research , Delhi High Court On , Delhi High Court , Public Interest Litigation , Central India , Indian Council , Medical Research , Solicitor General , Sheel Aggarwal , Bhasvar Aggarwal , Independent Researcher , Advocate Sacchin Puri , Homeostatic Mechanisms , High Dosage , Government Of India , Niti Aayog , Ublic Interest Litigation In India , Indian Council Of Medical Research , Covid 19 Pandemic In India , Biotechnology Amp Medical Research Nec ,

PIL seeks sale of Covid vaccines by SII, Bharat Biotech at Rs 150 per dose

A public interest litigation
(PIL) has been filed in the Bombay High Court challenging the different rates for COVID-19 vaccines for the Centre and state governments and requesting direction to the Serum Institute of India (SSI) and Bharat Biotech to sell their vaccines at a uniform rate of Rs 150 per dose.
The PIL, filed on April 24 by advocate Fayzan Khan and three law students, said the vaccine is presumed to be an essential commodity and hence its management and distribution cannot be left in the hands of private companies.
These pharma giants are milking the fear psychosis of the increased death rates due to COVID-19, it said. ....

Justice Dipankar Datta , Fayzan Khan , Justicegs Kulkarni , Bombay High Court , Central Drugs Laboratory , Serum Institute Of India , Serum Institute , Bharat Biotech , Chief Justice Dipankar Datta , Government Of India , Ublic Interest Litigation In India , Public Interest Law , Kamini Jaiswal , Surat Airport Action Committee , Bio Therapeutic Drugs , Harmaceuticals Nec , Chief Justice , Serum Institute Of India , Central Drugs , நீதி டிபங்கர் தத்தா , குண்டு உயர் நீதிமன்றம் , மைய மருந்துகள் ஆய்வகம் , சீரம் நிறுவனம் ஆஃப் இந்தியா , சீரம் நிறுவனம் , பாரத் பயோடெக் , தலைமை நீதி டிபங்கர் தத்தா ,